Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628062 | 1.00 | HTR6 (0.32) | HTR6HSD17B10 | |
| SCHEMBL7529722 | 1.00 | HTR6 (0.32) | HTR6HSD17B10 | |
| SCHEMBL905852 | 0.78 | KDM4E (0.44) | HTR6HSD17B10 | |
| SCHEMBL906133 | 0.78 | PTGDR2 (0.41) | HTR6 | |
| SCHEMBL7529719 | 0.76 | HTR6 (0.38) | HTR6HSD17B10 | |
| SCHEMBL905786 | 0.76 | HTR6 (0.38) | HTR6HSD17B10 | |
| SCHEMBL6628060 | 0.76 | HTR6 (0.38) | HTR6HSD17B10 | |
| SCHEMBL10199815 | 0.74 | HTR6 (0.40) | HTR6HSD17B10 | |
| SCHEMBL905719 | 0.71 | CA1 (0.46) | HTR6HSD17B10 | |
| SCHEMBL906064 | 0.71 | CA1 (0.46) | HTR6HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202965-B1 | INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RES LTD (GB) | 2004-10-13 | — | — | EP | claimed |
| US-6706750-B1 | USEFUL IN TREATING OBESITY AND OTHER DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-03-16 | — | — | US | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1202965-B1 | INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RES LTD (GB) | 2004-10-13 | — | — | EP | disclosed |
| US-6706750-B1 | USEFUL IN TREATING OBESITY AND OTHER DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR6 21/4885HSD17B10 2277/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR6 21/4885HSD17B10 2277/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR6 21/4885HSD17B10 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.